Objective: To study the effect of Xiongshao Capsule (芎芍胶囊, XSC), a TCM herb that can promote blood circulation to remove blood stasis, on the endothelial dependent relaxation function, serum nitric oxide (NO), and...Objective: To study the effect of Xiongshao Capsule (芎芍胶囊, XSC), a TCM herb that can promote blood circulation to remove blood stasis, on the endothelial dependent relaxation function, serum nitric oxide (NO), and plasma endothelin-KET-1) of the patients with cervical atherosclerosis. Methods: Forty patients were randomly divided into two groups; XSC group and Probucol group (western medicine control). In addition, 20 healthy people were set as a normal control group. Plasma ET-1, serum NO, the internal diameter of basal brachial artery, endothelial dependent flow mediated dilation (FMD) and non-endothelial dependent nitroglycerin induced dilation (NID) to the trial group before and after therapy and to the healthy control group were determined respectively. Results; Compared to the healthy control group, FMD of patients with atherosclerosis was damaged obviously, the serum NO level decreased, plasma ET-1 increased (P< 0. 01), NID also decreased (P<0. 05), the internal diameter of basal brachial artery has no obvious difference (P>0. 05). After the patients with atherosclerosis were treated with Xiongshao Capsule for 12 weeks, FMD increased evidently, plasma ET-1 decreased, serum NO and the ratio of NO/ET-1 increased, compared with the level before therapy and Probucol group, the difference was significant (P<0.05, P<0.01), NID didn't change obviously (P>0.05). Conclusion: XSC could regulate vascular activity factor and improve the function of endothelial dependent vascular dilation of patients with atherosclerosis.展开更多
Objective：To evaluate the safety and efficacy of Xiongshao Capsule（芎芍胶囊,XS）,consisting of Chuangxiongol and paeoniflorin,in preventing restenosis after percutaneous coronary intervention（PCI） in senile corona...Objective：To evaluate the safety and efficacy of Xiongshao Capsule（芎芍胶囊,XS）,consisting of Chuangxiongol and paeoniflorin,in preventing restenosis after percutaneous coronary intervention（PCI） in senile coronary heart disease（CHD） patients.Methods：A multi-center,randomized,double-blind,placebo-controlled trial was conducted.A total of 335 CHD patients were randomly assigned to treatment with oral administration of XS,or a placebo for 6 months after successful PCI.A clinical follow-up was performed at 1, 3 and 6 months after PCI and an angiographic follow-up was scheduled at 6 months.The primary endpoint was angiographic restenosis defined as a luminal stenosis≥50%in follow-up.The secondary endpoints were combined incidence of death,target lesion nonfatal myocardial infarction,repeat target-vessel angioplasty,and coronary artery bypass graft surgery（CABG）.The follow-up for the above clinical endpoint events was continued to 1 year after PCI.Results：The subgroup analysis of 152 senile patients（68 cases angiographic follow-up） showed that the restenosis rates tended to reduce in the XS group as compared with that in the placebo group （24.32%vs.38.71%,P0.05）,and the minimum lumen diameter（MLD） significantly increased in the follow-up （2.15±0.84 for XS vs.1.73±0.91 for placebo,P0.05）.The incidence of recurrent angina at 3 and 6 months after PCI was also significantly reduced in the XS group（4.11%and 12.33%） as compared with those in the placebo group（17.72%and 43.04%）,but there was no significant difference in the combined incidence of clinical outcomes（6.85%in the XS group vs.11.39%in the placebo group,P0.05）.No significant adverse reactions occurred within the 6-month follow-up period in the XS group.Conclusion：Administration of XS in addition to standardized Western medication for 6 months is demonstrated to be safe and effective in reducing post-PCI recurrent angina and inhibiting luminal restenosis after PCI in senile CHD patients.展开更多
Objective: To evaluate the effect of Xiongshao Capsule (XS, 芎芍胶囊) in preventing clinical and angiographic restenosis after coronary angioplasty or/and stenting. Methods: The total of 108 coronary heart disease pat...Objective: To evaluate the effect of Xiongshao Capsule (XS, 芎芍胶囊) in preventing clinical and angiographic restenosis after coronary angioplasty or/and stenting. Methods: The total of 108 coronary heart disease patients with successful coronary angioplasty or/and stenting were randomly divided into the control group (55 cases, routine treatment) and the XS group (53 cases, routine treatment combined with XS). The recurrence of angina, clinical end-point events, changing of blood-stasis syndrome score (BSSS) and coronary angiography within 6 month after coronary angioplasty or/and stenting were observed. Results: Follow-up angiography was performed in 42 patients including 18 cases in the XS group (restenosis was observed in 7 patients) and 24 cases in the control group (restenosis was observed in 17 patients), there was significant difference between the occurrence of restenosis in XS and that in control group (P<0.05). The occurrence of clinical end-point events (death, nonfatal target lesion myocardial infarction, coronary artery bypass graft surgery, or repeat target-vessel angioplasty) in the XS group (18.8%) was significantly lower than that in the control group (40%)(P<0.05). The recurrent angina was observed in 13 cases in the XS group, there was significant difference as compared with 27 cases in the control group (P<0.05). There was also remarkable significance for the difference of base-line and follow-up BSSS between groups (P<0.01). Logistic multivariate stepwise regress analysis and multivariate regress analysis of the related factors with restenosis confirmed by coronary angiography showed that, the base-line BSSS and the difference of base-line and follow-up BSSS were important influencing factors on the occurrence of restenosis after interventional treatment (P<0.05). Conclusion: XS could markedly reduce the occurrence of angiographic restenosis, clinical end-point events and recurrent angina, improve condition of blood-stasis after coronary angioplasty or/and stenting. The severity of blood-stasis syndrome was an important influencing factor on the occurrence of restenosis. It still needs to be further demonstrated by large-scale, double-blinded, randomized and controlled study.展开更多
Objective: To study the effect of Xiongshao capsule (XSC) on vascular remodeling in porcine coronary balloon injury model. Methods: Coronary artery restenosis model was established by oversized balloon injury at mid-r...Objective: To study the effect of Xiongshao capsule (XSC) on vascular remodeling in porcine coronary balloon injury model. Methods: Coronary artery restenosis model was established by oversized balloon injury at mid-region of the left anterior descending coronary artery. They were divided into 5 groups, untreated or treated with probucol, Xueguantong, low and high dose of XSC respectively, and compared. The effect of XSC on late lumen loss resulted from vascular remodeling was evaluated by quantitative histological method with combining histopathological analysis and coronary angiographic examination. Results: The (59±20)% of late lumen loss was caused by vascular remodeling and (41±20)% caused by intimal hyperplasia. Compared with the control group, all the treatment could significantly reduce the late lumen loss after balloon injury (P<0.05 or P<0.01), both low and high dose of XSC could significantly reduce the late lumen loss caused by remodeling (P<0.05 and P<0.01 respectively). Conclusion: Vascular remodeling plays an important role in late lumen stenosis formation in coronary artery after balloon injury. XSC could significantly inhibit the pathological vascular remodeling, and thus reduce the late lumen loss and prevent the restenosis of the injured coronary artery.展开更多
Objective： To evaluate the angiogenic effect of the Xiongshao capsule （芎芍胶囊, XSC） in human umbilical vein endothelial cells （HUVEC）, and to investigate the possible molecular mechanisms mediating its biologic...Objective： To evaluate the angiogenic effect of the Xiongshao capsule （芎芍胶囊, XSC） in human umbilical vein endothelial cells （HUVEC）, and to investigate the possible molecular mechanisms mediating its biological effect. Methods： Serum pharmacology was applied in this study, in which different doses of XSC were administrated to rats orally and then XSC-containing serum （XSC-S） was collected for the following in vitro experiments. The viability of HUVEC was determined by the 3-（4, 5-dimethylthiazol-2-yl）-2, 5-diphenyltetrazolium bromide （MTT） assay. Cell density was observed via phase-contrast microscopy. Fluorescence-activated cell sorting analysis with propidium iodide staining was performed to determine cell cycle phase. Cell migration was determined by wound-healing method. Capillary tube formation by HUVEC was examined using ECMatrix gel- based assay. Vascular endothelial growth factor （VEGF） and basic fibroblast growth factor （bFGF） expression levels were measured by reverse transcription polymerase chain reaction （RT-PCR） and enzyme-linked immunosorbant assay （ELISA） analyses. Results： XSC-S dose-dependently stimulated proliferation of HUVEC by promoting the cell cycle G1 to S progression. In addition, XSC-S treatment dramatically increased the migration and capillary tube formation of HUVEC in a dose-dependent manner. Moreover, XSC-S enhanced the expression of VEGF and bFGF at both mRNA and protein levels. Conclusion： XSC can promote several features of angiogenesis in endothelial cells through up-regulating the expression of bFGF and VEGF, suggesting that XSC may be a potential novel therapeutic agent for the treatment of ischemic heart diseases.展开更多
文摘Objective: To study the effect of Xiongshao Capsule (芎芍胶囊, XSC), a TCM herb that can promote blood circulation to remove blood stasis, on the endothelial dependent relaxation function, serum nitric oxide (NO), and plasma endothelin-KET-1) of the patients with cervical atherosclerosis. Methods: Forty patients were randomly divided into two groups; XSC group and Probucol group (western medicine control). In addition, 20 healthy people were set as a normal control group. Plasma ET-1, serum NO, the internal diameter of basal brachial artery, endothelial dependent flow mediated dilation (FMD) and non-endothelial dependent nitroglycerin induced dilation (NID) to the trial group before and after therapy and to the healthy control group were determined respectively. Results; Compared to the healthy control group, FMD of patients with atherosclerosis was damaged obviously, the serum NO level decreased, plasma ET-1 increased (P< 0. 01), NID also decreased (P<0. 05), the internal diameter of basal brachial artery has no obvious difference (P>0. 05). After the patients with atherosclerosis were treated with Xiongshao Capsule for 12 weeks, FMD increased evidently, plasma ET-1 decreased, serum NO and the ratio of NO/ET-1 increased, compared with the level before therapy and Probucol group, the difference was significant (P<0.05, P<0.01), NID didn't change obviously (P>0.05). Conclusion: XSC could regulate vascular activity factor and improve the function of endothelial dependent vascular dilation of patients with atherosclerosis.
基金Supported by the grant from National Tenth Five-year Projects Plan(No.2001BA701A20)
文摘Objective：To evaluate the safety and efficacy of Xiongshao Capsule（芎芍胶囊,XS）,consisting of Chuangxiongol and paeoniflorin,in preventing restenosis after percutaneous coronary intervention（PCI） in senile coronary heart disease（CHD） patients.Methods：A multi-center,randomized,double-blind,placebo-controlled trial was conducted.A total of 335 CHD patients were randomly assigned to treatment with oral administration of XS,or a placebo for 6 months after successful PCI.A clinical follow-up was performed at 1, 3 and 6 months after PCI and an angiographic follow-up was scheduled at 6 months.The primary endpoint was angiographic restenosis defined as a luminal stenosis≥50%in follow-up.The secondary endpoints were combined incidence of death,target lesion nonfatal myocardial infarction,repeat target-vessel angioplasty,and coronary artery bypass graft surgery（CABG）.The follow-up for the above clinical endpoint events was continued to 1 year after PCI.Results：The subgroup analysis of 152 senile patients（68 cases angiographic follow-up） showed that the restenosis rates tended to reduce in the XS group as compared with that in the placebo group （24.32%vs.38.71%,P0.05）,and the minimum lumen diameter（MLD） significantly increased in the follow-up （2.15±0.84 for XS vs.1.73±0.91 for placebo,P0.05）.The incidence of recurrent angina at 3 and 6 months after PCI was also significantly reduced in the XS group（4.11%and 12.33%） as compared with those in the placebo group（17.72%and 43.04%）,but there was no significant difference in the combined incidence of clinical outcomes（6.85%in the XS group vs.11.39%in the placebo group,P0.05）.No significant adverse reactions occurred within the 6-month follow-up period in the XS group.Conclusion：Administration of XS in addition to standardized Western medication for 6 months is demonstrated to be safe and effective in reducing post-PCI recurrent angina and inhibiting luminal restenosis after PCI in senile CHD patients.
文摘Objective: To evaluate the effect of Xiongshao Capsule (XS, 芎芍胶囊) in preventing clinical and angiographic restenosis after coronary angioplasty or/and stenting. Methods: The total of 108 coronary heart disease patients with successful coronary angioplasty or/and stenting were randomly divided into the control group (55 cases, routine treatment) and the XS group (53 cases, routine treatment combined with XS). The recurrence of angina, clinical end-point events, changing of blood-stasis syndrome score (BSSS) and coronary angiography within 6 month after coronary angioplasty or/and stenting were observed. Results: Follow-up angiography was performed in 42 patients including 18 cases in the XS group (restenosis was observed in 7 patients) and 24 cases in the control group (restenosis was observed in 17 patients), there was significant difference between the occurrence of restenosis in XS and that in control group (P<0.05). The occurrence of clinical end-point events (death, nonfatal target lesion myocardial infarction, coronary artery bypass graft surgery, or repeat target-vessel angioplasty) in the XS group (18.8%) was significantly lower than that in the control group (40%)(P<0.05). The recurrent angina was observed in 13 cases in the XS group, there was significant difference as compared with 27 cases in the control group (P<0.05). There was also remarkable significance for the difference of base-line and follow-up BSSS between groups (P<0.01). Logistic multivariate stepwise regress analysis and multivariate regress analysis of the related factors with restenosis confirmed by coronary angiography showed that, the base-line BSSS and the difference of base-line and follow-up BSSS were important influencing factors on the occurrence of restenosis after interventional treatment (P<0.05). Conclusion: XS could markedly reduce the occurrence of angiographic restenosis, clinical end-point events and recurrent angina, improve condition of blood-stasis after coronary angioplasty or/and stenting. The severity of blood-stasis syndrome was an important influencing factor on the occurrence of restenosis. It still needs to be further demonstrated by large-scale, double-blinded, randomized and controlled study.
文摘Objective: To study the effect of Xiongshao capsule (XSC) on vascular remodeling in porcine coronary balloon injury model. Methods: Coronary artery restenosis model was established by oversized balloon injury at mid-region of the left anterior descending coronary artery. They were divided into 5 groups, untreated or treated with probucol, Xueguantong, low and high dose of XSC respectively, and compared. The effect of XSC on late lumen loss resulted from vascular remodeling was evaluated by quantitative histological method with combining histopathological analysis and coronary angiographic examination. Results: The (59±20)% of late lumen loss was caused by vascular remodeling and (41±20)% caused by intimal hyperplasia. Compared with the control group, all the treatment could significantly reduce the late lumen loss after balloon injury (P<0.05 or P<0.01), both low and high dose of XSC could significantly reduce the late lumen loss caused by remodeling (P<0.05 and P<0.01 respectively). Conclusion: Vascular remodeling plays an important role in late lumen stenosis formation in coronary artery after balloon injury. XSC could significantly inhibit the pathological vascular remodeling, and thus reduce the late lumen loss and prevent the restenosis of the injured coronary artery.
基金Supported by the Developmental Fund of CHEN Ke-ji Integrative Medicine(No.CKJ 2008056 and CKJ 2010019)
文摘Objective： To evaluate the angiogenic effect of the Xiongshao capsule （芎芍胶囊, XSC） in human umbilical vein endothelial cells （HUVEC）, and to investigate the possible molecular mechanisms mediating its biological effect. Methods： Serum pharmacology was applied in this study, in which different doses of XSC were administrated to rats orally and then XSC-containing serum （XSC-S） was collected for the following in vitro experiments. The viability of HUVEC was determined by the 3-（4, 5-dimethylthiazol-2-yl）-2, 5-diphenyltetrazolium bromide （MTT） assay. Cell density was observed via phase-contrast microscopy. Fluorescence-activated cell sorting analysis with propidium iodide staining was performed to determine cell cycle phase. Cell migration was determined by wound-healing method. Capillary tube formation by HUVEC was examined using ECMatrix gel- based assay. Vascular endothelial growth factor （VEGF） and basic fibroblast growth factor （bFGF） expression levels were measured by reverse transcription polymerase chain reaction （RT-PCR） and enzyme-linked immunosorbant assay （ELISA） analyses. Results： XSC-S dose-dependently stimulated proliferation of HUVEC by promoting the cell cycle G1 to S progression. In addition, XSC-S treatment dramatically increased the migration and capillary tube formation of HUVEC in a dose-dependent manner. Moreover, XSC-S enhanced the expression of VEGF and bFGF at both mRNA and protein levels. Conclusion： XSC can promote several features of angiogenesis in endothelial cells through up-regulating the expression of bFGF and VEGF, suggesting that XSC may be a potential novel therapeutic agent for the treatment of ischemic heart diseases.
